Keywords: Lupus erythematosus, Market forecasts, Benlysta, GlaxoSmithKline, Decision Resources

Benlysta will be lupus market leader in 2021 with sales of more than $1.7 billion, says DR

Article | 25 October 2012

Print This

In the systemic lupus erythematosus (SLE) drug market, Human Genome Sciences/GlaxoSmithKline’s (LSE: GSK) Benlysta (belimumab), will be ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in